Orphine opioids are rapidly becoming one of the most serious drug threats facing the United Kingdom. Government advisers are now warning that urgent action is needed before more lives are lost.

On 30 April 2026, the Advisory Council on the Misuse of Drugs (ACMD) published its seventh addendum to a major report on novel opioids. This time, it focused on a group of compounds known as orphine opioids. The findings are stark: since spring 2025, more than 15 people have died in England alone, with cychlorphine and spirochlorphine identified in the fatal cases.

What Are Orphine Opioids?

Orphine opioids are not entirely new to science. Their origins trace back to the 1960s, when Belgian pharmacologist Paul Janssen explored a broad range of compounds as potential analgesics. His parallel work on fentanyls ultimately took precedence. Only one orphine variant, bezitramide, ever reached the market. Even that was withdrawn in 2004 after a number of fatalities.

Decades later, the same chemical family is resurfacing, but not in hospitals. NPS suppliers now actively develop orphine opioids as alternatives to fentanyls and nitazenes, which are increasingly falling under international controls. Some of these newer compounds carry opioid agonist potencies comparable to or exceeding fentanyl. Others reportedly approach the potency of carfentanil, a substance so extreme it was once considered as a euthanising agent for stranded whales.

The Scale of the Orphine Opioid Crisis

The figures are alarming. The National Crime Agency (NCA) and the Office for Health Improvement and Disparities (OHID) confirmed more than 15 deaths in England involving orphine opioids since spring 2025. The National Programme on Substance Use Mortality (NPSUM) identified 14 orphine detections from coroner-reported inquests in England and Wales. Of those, 11 involved cychlorphine and three involved chlorphine.

This problem extends well beyond the UK. The United Nations Office on Drugs and Crime (UNODC) received 206 reports from multiple countries through its Early Warning Advisory programme, all identifying drug samples containing orphine compounds. In the United States, authorities documented 60 post-mortem toxicology cases specifically involving cychlorphine.

Seven compounds currently circulate in UK and European drug markets without control under the Misuse of Drugs Act (MDA) 1971. All fall under the Psychoactive Substances Act 2016, but that alone is not enough. The seven compounds are chlorphine, cychlorphine, spirochlorphine, 5,6-dichloro desmethylchlorphine, etodezitramide, spirobrorphine, and 5,6-dichlorobrorphine.

Why Synthetic Opioid NPS Cause Such Serious Harm

The danger of synthetic opioid NPS like orphines comes down to both potency and unfamiliarity. Scientific literature on many of these compounds remains thin. Clinicians, harm reduction workers, and emergency services often have little prior knowledge of what they are dealing with when a patient presents.

Certain variants stand out as particularly dangerous. Etodezitramide has already appeared on European NPS websites and Welsh drug testing services have identified it in the UK. Its potency reportedly exceeds fentanyl by many times. Cyetodezitramide is expected to be even stronger. Etospirotramide may be equipotent to 3-methylfentanyl, a compound with a notorious history in mass casualty events.

The Medicines and Healthcare products Regulatory Agency (MHRA) holds no records of clinical trials, unlicensed imports, or licensing applications for any of the orphine or spirorphine compounds in this report. Simply put, none of these substances carry any recognised medical use.

The Push to Control Orphine Opioids Under Class A

The ACMD’s position is clear. The Council wants all seven named orphine opioids added urgently to Class A of the Misuse of Drugs Act 1971 and Schedule 1 of the Misuse of Drugs Regulations 2001. That would place them alongside heroin and cocaine at the highest level of control.

The ACMD goes further still. It also wants two generic definitions introduced to capture the broader orphine opioid family. This prevents manufacturers from slightly altering a compound’s structure to produce something technically legal but equally dangerous. The approach mirrors generic controls already in place for nitazene-type drugs.

The two proposed generics are broad by design. The first covers orphine-like materials built around a benzimidazolone core. The second covers spirorphine-like materials, which share a related but structurally distinct triazaspiro core. Both draw partly on updated German drug legislation, which introduced its own generic definitions for similar compounds in 2026.

If full Class A controls face parliamentary delays, the ACMD recommends a Temporary Class Drug Order (TCDO) for the seven named compounds. A TCDO would increase penalties for manufacture, importation, and supply in the interim. There is one complication worth noting: a TCDO would remove these compounds from the scope of the Psychoactive Substances Act 2016. That could create a gap around possession offences in custodial settings, an issue the ACMD acknowledges but does not regard as a reason to delay action.

A Race Against the Chemists

There is a familiar dynamic at work here. Every time authorities control a class of opioid NPS, suppliers adapt. They tweak a molecule, produce a new variant, and the cycle begins again. Generic controls are the most effective legislative tool available to break that cycle, but writing them is a precise and difficult task.

In this case, Janssen’s original research on orphines also gave rise to compounds with antipsychotic uses, including benperidol and droperidol. The ACMD consulted specialists in chemical regulation to ensure the proposed generics capture genuinely dangerous compounds without sweeping in legitimate pharmaceuticals.

What Happens Next

The Home Office now holds responsibility for enacting these controls. The goal is simple: add seven named orphine opioids and two generic definitions to Class A of the Misuse of Drugs Act 1971 as a matter of urgency.

The death toll is real. The international spread of these synthetic opioid NPS is documented. With 206 reports from countries worldwide and confirmed fatalities mounting on both sides of the Atlantic, the ACMD has made its position clear. The next move belongs to ministers.

Source: dbrecoveryresources